Furthermore, decreased NRF2 expression was shown to attenuate colony formation and tumor development from A375 cell xenograft in heterotopic murine models, supporting the notion that the combined use of Brusatol and UVA might offer a valuable therapeutic option against malignant melanoma through the disruption of the tumor antioxidant defenses [291] (see Table 1). This evidence concerns the gene NFE2L2 and neoplasm.